REG - Allergy Therapeutics - Result of AGM

Allergy TherapeuticsAnnouncement

07/02/2023 18:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230207:nRSG2264Pa&default-theme=true

RNS Number : 2264P  Allergy Therapeutics PLC  07 February 2023

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

 

Result of Annual General Meeting

 

 

7 February 2023 Allergy Therapeutics plc (AIM:AGY), the fully integrated
specialty pharmaceutical group specialising in allergy vaccines, announces
that all resolutions proposed at the 2022 Annual General Meeting ("AGM") held
today were duly passed by shareholders on a show of hands.

 

Resolutions 1 to 10 (inclusive) were proposed as ordinary resolutions and
resolution 11 was proposed as a special resolution. The results of the proxy
votes received ahead of the meeting are outlined in the table below.

 

 

 Resolution                                                                  For:           %age   Against:   %age  Total Votes Cast  % of ISC  Withheld
 1. To re-elect Manual Llobet as a Director                                  220,438,209    99.55  438,504    0.20  220,876,713       32.52     112,037
 To re-elect Cheryl MacDiarmid as a Director                                 220,433,972    99.55  448,778    0.20  220,882,750       32.53     106,000
 3. To re-elect Anthony Parker as a Director                                 218,552,445    98.70  2,324,268  1.05  220,876,713       32.52     112,037
 4. To re-elect Zheqing (Simon) Shen as a Director                           218,556,682    98.70  2,326,068  1.05  220,882,750       32.53     106,000
 5. To re-elect Mary Tavener as a Director                                   220,433,972    99.55  442,741    0.20  220,876,713       32.52     112,037
 6. To re-elect Tunde Otulana as a Director                                  220,433,972    99.55  442,741    0.20  220,876,713       32.43     112,037
 7. To re-elect Peter Jensen as a Director                                   217,599,392    98.55  2,641,372  1.20  220,240,764       32.43     747,986
 8. To re-appoint BDO LLP as auditors of the Company                         218,640,401    99.63  235,796    0.11  218,876,197       32.23     2,112,553
 9. To authorise the Directors to agree the Auditors remuneration            217,956,401    99.31  938,759    0.43  218,895,160       32.23     2,093,590
 10. To authorise the Directors to allot the unissued share capital up to a  220,517,191    99.58  366,559    0.17  220,883,750       32.53     105,000
 specific amount (s.551)
 11. Special Resolution:                                                     220,515,891    99.60  336,822    0.15  220,852,713       32.52     136,037

 To adopt the Articles of Association

 

 

 

- ENDS -

 

 

 

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0)1903 845 820

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

 

Panmure Gordon (Nominated Adviser and Broker)

+44 (0)20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

 

Consilium Strategic Communications

+44 (0)20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third-party
products from its subsidiaries in nine major European countries and via
distribution agreements in an additional ten countries. Its broad pipeline of
products in clinical development includes vaccines for grass, tree, house dust
mite and peanut. For more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSSAFAWEDSEEE